NEW YORK (GenomeWeb News) – Expression Analysis and RainDance Technologies will collaborate to offer researchers services that can characterize rare genetic mutations relevant to complex diseases, particularly cancer, Expression Analysis said today.

The company said that the firms will work together with and sponsor eight researchers to "define a panel of high-priority genomic targets" that would be used in large-scale re-sequencing studies of cancer samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.